Kailera Therapeutics, Inc.
NASDAQ:KLRABiotechnology
Healthcare
$11.79 +2.66%
+$0.51 today
- Market cap
- $1.53B
- Beta
- 0.00
52W Low $18.50High $28.23
Volume 0.42M
Average 0.80M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$120.21M
FY 2025 · Annual
Investing Cash Flow
-$492.60M
FY 2025 · Annual
Financing Cash Flow
$598.66M
FY 2025 · Annual
Cash Flow Statement
USD
Metric | FY2025 Dec 2025 |
|---|---|
| Net Income | (148.96M) |
| Depreciation & Amortization | 310K |
| Deferred Income Tax | 0 |
| Stock-Based Compensation | 10.94M |
| Change in Working Capital | 16.78M |
| Accounts Receivables | 0 |
| Inventory | 0 |
| Accounts Payables | 4.69M |
| Other Working Capital | 12.09M |
| Other Non-Cash Items | 714K |
| Operating Cash Flow | (120.21M) |
| Capital Expenditures | (2.09M) |
| Acquisitions (Net) | 0 |
| Purchases of Investments | (632.16M) |
| Sales of Investments | 141.65M |
| Other Investing Activities | 0 |
| Investing Cash Flow | (492.6M) |
| Debt Repayment | 100M |
| Common Stock Issued | 498.97M |
| Common Stock Repurchased | 0 |
| Dividends Paid | 0 |
| Other Financing Activities | (499.19M) |
| Financing Cash Flow | 598.66M |
| Effect of Forex Changes | 0 |
| Net Change in Cash | (14.15M) |
| Free Cash Flow | (122.3M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$149.0M
+ D&A$310.0K
+ Stock-Based Comp$10.9M
+ Deferred Tax$0
+ Working Capital$16.8M
+ Other Non-Cash$714.0K
= Operating Cash Flow-$120.2M
- Capex-$2.1M
= Free Cash Flow-$122.3M
Analysis
FY2025 free cash flow is -$122.3M. FCF conversion is 82.1% of net income. Operating cash flow was -$120.2M, with capex of -$2.1M. The largest bridge item is Working Capital at $16.8M.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 4, 2026 | |
| 8-K | Current report | Nov 4, 2026 | |
| 3 | Initial statement of beneficial ownership | Sep 9, 2026 | |
| 4 | Statement of changes in beneficial ownership | Sep 9, 2026 | |
| SC 13G | SC 13G filing | Aug 14, 2026 |
Does KLRA generate free cash flow?
Kailera Therapeutics, Inc. (KLRA) generated -$122.30M of free cash flow in fiscal 2025.
How much operating cash flow does KLRA produce?
Operating cash flow was -$120.21M, before capital expenditures of $2.09M.
Continue the stock analysis
Jump to another research area for this company.